No annual revenue total was found in Cell Source, Inc.'s SEC filings.
Cell Source, Inc. (CLCS) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Mar 31, 2025 it held $1,240 in cash and investments and $314,985 in total debt.
Revenue
—
Net income (TTM)
$-4.72M
+3.8% vs year-ago TTM
Operating cash flow (TTM)
$-3.11M
-40.6% vs year-ago TTM
Free cash flow
$-3.12M
EPS (TTM)
$-0.14
+10.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
67.95M
+65.6% vs prior year
Net cash
$-313,745
as of Mar 31, 2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLCS (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1569340
- Former names
- TICKET TO SEE, INC. (until Jun 26, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
| Operating income | -$3.8M | -$4.3M | -$4.2M | -$4.0M | -$3.6M |
| Net income | -$4.5M | -$5.3M | -$5.2M | -$5.5M | -$4.6M |
| Diluted EPS | -$0.14 | -$0.17 | -$0.18 | — | — |
| Operating cash flow | -$2.7M | -$2.3M | -$3.1M | -$3.4M | -$2.8M |
| Total assets | $286,500 | $195,171 | $409,845 | $313,767 | $452,339 |
| Total liabilities | $18.8M | $15.8M | $13.0M | — | $8.4M |
| Stockholders' equity | -$18.5M | -$15.6M | -$12.6M | -$9.8M | -$7.9M |
| Cash and investments | $74,631 | $22,203 | — | $93,095 | — |
| Total debt | $314,985 | $42,033 | — | $27,926 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2025 |
| 10-K | Annual report | Apr 7, 2026 | Dec 31, 2024 |
| 8-K |
Current report
Auditor change
|
Jun 27, 2025 | Jun 26, 2025 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| 10-Q | Quarterly report | Aug 19, 2024 | Jun 30, 2024 |
| 10-Q | Quarterly report | Jul 29, 2024 | Mar 31, 2024 |
All 139 Cell Source, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.